Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1326).(01).Cardiology Case No 46. Suspected Chronic Coronary Syndrome (IHD) with Hypertension and Moderate Concentric LVH; Preserved LVEF (69%).(Prescription 1)4545

(Prescription attached):-

đŸŠē āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻŦāĻŋāĻļā§āϞ⧇āώāĻŖ āĻ“ Clinical Diagnostic Assessment

Patient: Fatema Begum | Age: 56 Years

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύāϟāĻŋ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ Diagnosis, Examination Findings, Investigations, Treatment Plan āĻāĻŦāĻ‚ āĻ›āϝāĻŧāϟāĻŋ āĻ“āώ⧁āϧ⧇āϰ Generic Name, MedEx Therapeutic Class, āĻŦā§āϝāĻŦāĻšāĻžāϰ, āĻŽā§‚āĻ˛ā§āϝ āĻ“ āϰ⧋āĻ—ā§€āϕ⧇ āĻĻ⧇āĻ“āϝāĻŧāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖ āύāĻŋāĻšā§‡ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž āĻ•āϰāĻ›āĻŋāĨ¤

āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāώāϝāĻŧ: āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• IHD with HTN āϞāĻŋāϖ⧇āϛ⧇āύāĨ¤ āϤāĻŦ⧇ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻ•āϰ⧋āύāĻžāϰāĻŋ āφāĻ°ā§āϟāĻžāϰāĻŋāϤ⧇ āĻŦā§āϞāϕ⧇āĻœā§‡āϰ āύāĻŋāĻļā§āϚāĻŋāϤ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχāĨ¤ āĻ…āĻ¨ā§āϝāĻĻāĻŋāϕ⧇ Echocardiography-āϤ⧇ Moderate Concentric Left Ventricular Hypertrophy āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϛ⧇, āϝāĻž āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ⧇āϰ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻ āĻ›āĻžāĻĄāĻŧāĻž āϰ⧋āĻ—ā§€āϰ āϰāĻ•ā§āϤāϚāĻžāĻĒ 95/63 mmHg, āϝāĻž āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻĻ⧇āĻ“āϝāĻŧāĻž BP-āĻ•āĻŽāĻžāύ⧋āϰ āĻ“āώ⧁āϧāϗ⧁āϞ⧋āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤


ā§§. Patient History āĻ“ Chief Complaints (C/C)

āĻŦāĻŋāώāϝāĻŧāĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϤāĻĨā§āϝ
Patient NameFatema Begum
Age56 Years
Prescription Date05/01/2026
Chief Complaints (C/C)āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Previous HTNDiagnosis-āĻ HTN āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇
Previous IHDDiagnosis-āĻ IHD āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇
Diabetes MellitusāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Smoking HistoryāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Family HistoryāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Previous MI/PCI/CABGāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ
Drug AllergyāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχ

Clinical Interpretation:

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϰ⧋āĻ—ā§€āϰ IHD āĻāĻŦāĻ‚ HTN āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āϛ⧇āύāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻŦ⧁āϕ⧇ āĻŦā§āϝāĻĨāĻž, āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ, āĻĒāϰāĻŋāĻļā§āϰāĻŽā§‡ āĻŦ⧁āĻ•āĻŦā§āϝāĻĨāĻž, āĻ•āϤāĻĻāĻŋāύ āϧāϰ⧇ āωāĻĒāϏāĻ°ā§āĻ—, āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻšāĻžāĻ°ā§āϟ āĻ…ā§āϝāĻžāϟāĻžāĻ• āĻ•āĻŋāĻ‚āĻŦāĻž Coronary Angiography-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āύāύāĻŋāĨ¤

āϏ⧁āϤāϰāĻžāĻ‚ āĻāϗ⧁āϞ⧋āϕ⧇ Documented Clinical Diagnosis āĻŦāϞāĻž āϝāĻžāϝāĻŧ, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻŦāĻŋāĻ¸ā§āϤāĻžāϰāĻŋāϤ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āĻšāĻŋāϏ⧇āĻŦ⧇ āϧāϰ⧇ āύ⧇āĻ“āϝāĻŧāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Confidence: 0.99 — āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āωāĻ˛ā§āϞāĻŋāĻ–āĻŋāϤ āϤāĻĨā§āϝ⧇āϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇āĨ¤


⧍. On Examination (O/E)

ExaminationResultInterpretation
Blood Pressure95/63 mmHgāϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻ•āĻŽ
Pulse74 beats/mināĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• resting pulse range
Respiratory RateāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻž
SpO₂āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻž
Chest ExaminationāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻž
Cardiac AuscultationāωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻž

Clinical Significance

BP 95/63 mmHg

āϰ⧋āĻ—ā§€āϰ HTN-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻ•āϞ⧇āĻ“ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻŽāϝāĻŧ āϰāĻ•ā§āϤāϚāĻžāĻĒ āĻŦ⧇āĻļāĻŋ āĻ›āĻŋāϞ āύāĻžāĨ¤

āϰ⧋āĻ—ā§€āϕ⧇ āϤāĻŋāύāϟāĻŋ BP-āĻ•āĻŽāĻžāύ⧋āϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāϝ⧁āĻ•ā§āϤ āĻ“āώ⧁āϧ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇:

  • Olmesartan
  • Metoprolol
  • Nitroglycerin

āĻāϗ⧁āϞ⧋āϰ āϏāĻŽā§āĻŽāĻŋāϞāĻŋāϤ āĻĒā§āϰāĻ­āĻžāĻŦ⧇ Hypotension āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āϤāĻŦ⧇ 95/63 mmHg-āĻāϰ āĻāĻ•āϟāĻŋ āϰāĻŋāĻĄāĻŋāĻ‚ āĻĨ⧇āϕ⧇āχ āϰ⧋āĻ—ā§€āϕ⧇ āύāĻŋāĻļā§āϚāĻŋāϤāĻ­āĻžāĻŦ⧇ Hypotensive āĻŦāϞāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤ āϰ⧋āĻ—ā§€āϰ āωāĻĒāϏāĻ°ā§āĻ—, āφāϗ⧇āϰ BP āĻāĻŦāĻ‚ āĻĒ⧁āύāϰāĻžāϝāĻŧ BP āĻŽāĻžāĻĒāĻžāϰ āĻĢāϞ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Clinical Recommendation: āϰ⧋āĻ—ā§€ āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻāϏāĻŦ āĻ“āώ⧁āϧ āϖ⧇āϞ⧇ BP āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āĻāĻŦāĻ‚ āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž, āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻŦāĻž āĻ…āĻœā§āĻžāĻžāύ āĻšāĻ“āϝāĻŧāĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻ•āϞ⧇ āĻĻā§āϰ⧁āϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻĄā§‹āϜ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤ āύāĻŋāĻœā§‡ āĻĨ⧇āϕ⧇ Metoprolol āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύ⧋ āĻ“āώ⧁āϧ āĻšāĻ āĻžā§Ž āĻŦāĻ¨ā§āϧ āĻ•āϰāĻž āωāϚāĻŋāϤ āύāϝāĻŧāĨ¤


ā§Š. Doctor’s Diagnosis (Dx)

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϞāĻŋāϖ⧇āϛ⧇āύ:

IHD WITH HTN

āĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨ:

āχāĻ¸ā§āϕ⧇āĻŽāĻŋāĻ• āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āϏāĻ™ā§āϗ⧇ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒāĨ¤

A. IHD — Ischemic Heart Disease

Definition: āĻ•āϰ⧋āύāĻžāϰāĻŋ āϰāĻ•ā§āϤāύāĻžāϞāĻŋāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻšā§ƒāĻĻā§â€ŒāĻĒ⧇āĻļāĻŋāϰ āĻ…āĻ•ā§āϏāĻŋāĻœā§‡āύ⧇āϰ āϚāĻžāĻšāĻŋāĻĻāĻž āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āϰāĻ•ā§āϤ āϏāϰāĻŦāϰāĻžāĻš āύāĻž āĻšāϞ⧇ Myocardial Ischemia āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āϏāĻžāϧāĻžāϰāĻŖ āĻ•āĻžāϰāĻŖ āĻšāϞ⧋ Coronary Atherosclerosis, āϤāĻŦ⧇ Coronary Microvascular Dysfunction āĻŦāĻž Coronary Vasospasm-āĻāϰ āĻ•āĻžāϰāϪ⧇āĻ“ Ischemia āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĒāϏāĻ°ā§āĻ—:

  • āĻŦ⧁āϕ⧇ āϚāĻžāĻĒ āĻŦāĻž āĻŦā§āϝāĻĨāĻž
  • āĻĒāϰāĻŋāĻļā§āϰāĻŽā§‡ āĻŦ⧁āϕ⧇ āĻ…āĻ¸ā§āĻŦāĻ¸ā§āϤāĻŋ
  • āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ
  • āĻŦā§āϝāĻĨāĻž āĻŦāĻžāĻŽ āĻšāĻžāϤ, āĻšā§‹āϝāĻŧāĻžāϞ āĻŦāĻž āĻĒāĻŋāϠ⧇ āĻ›āĻĄāĻŧāĻŋāϝāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻž

āĻāχ āωāĻĒāϏāĻ°ā§āĻ—āϗ⧁āϞ⧋ āϰ⧋āĻ—ā§€āϰ āφāϛ⧇ āĻŦāϞ⧇ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤

B. HTN — Hypertension

Definition: āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒāĨ¤

āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ HTN āĻĨāĻžāĻ•āϞ⧇ Left Ventricle-āĻāϰ āĻĻ⧇āϝāĻŧāĻžāϞ āĻĒ⧁āϰ⧁ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻāϟāĻŋāϕ⧇ Left Ventricular Hypertrophy (LVH) āĻŦāϞāĻž āĻšāϝāĻŧāĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ Echo-āϤ⧇ LVH āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϛ⧇āĨ¤


ā§Ē. Investigation Report Analysis

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻĒāĻžāρāϚāϟāĻŋ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇āĨ¤

InvestigationReportClinical Interpretation
Echo 2DLVEF 69%LV systolic function preserved
Regional Wall MotionNo RWMA at restāĻŦāĻŋāĻļā§āϰāĻžāĻŽ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϝāĻŧ āĻĻ⧇āϝāĻŧāĻžāϞ⧇āϰ āφāĻžā§āϚāϞāĻŋāĻ• āϏāĻ‚āϕ⧋āϚāύ⧇ āĻ…āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āϤāĻž āĻĒāĻžāĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋ
LV StructureModerate Concentric LVHāĻŦāĻžāĻŽ āϭ⧇āĻ¨ā§āĻŸā§āϰāĻŋāĻ•āϞ⧇āϰ āĻĻ⧇āϝāĻŧāĻžāϞ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāĻ¤ā§āϰāĻžāϝāĻŧ āĻĒ⧁āϰ⧁
Chamber DimensionsWithin normal limitsāĻšā§‡āĻŽā§āĻŦāĻžāϰ⧇āϰ āĻŽāĻžāĻĒ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•
RBG4.7āĻāĻ•āĻ• āĻĻ⧇āĻ“āϝāĻŧāĻž āύ⧇āχ; mmol/L āĻšāϞ⧇ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāϕ⧇āϰ āĻŽāĻ§ā§āϝ⧇
Serum Creatinine1.1āĻāĻ•āĻ• āĻ“ eGFR āĻ›āĻžāĻĄāĻŧāĻž āĻĒā§‚āĻ°ā§āĻŖ renal assessment āϏāĻŽā§āĻ­āĻŦ āύāϝāĻŧ
Troponin I<0.006āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ reference range āĻ“ unit āĻĒā§āϰāϝāĻŧā§‹āϜāύ
CXR (P/A)CardiomegalyX-ray-āϤ⧇ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ āĻŦāĻĄāĻŧ āĻĻ⧇āĻ–āĻž āϗ⧇āϛ⧇

āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ Echocardiography Findings

1. LVEF = 69%

Left Ventricular Ejection Fraction āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϏ⧀āĻŽāĻžāϝāĻŧ āϰāϝāĻŧ⧇āϛ⧇āĨ¤

āĻāϟāĻŋ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ•āϰ⧇ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻŦāĻžāĻŽ āϭ⧇āĻ¨ā§āĻŸā§āϰāĻŋāĻ•āϞ⧇āϰ Systolic Pumping Function āϏāĻ‚āϰāĻ•ā§āώāĻŋāϤāĨ¤

Confidence: 0.99

2. Moderate Concentric LV Hypertrophy

āĻāϟāĻŋ āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ abnormal findingāĨ¤

Concentric LVH-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻŦāĻžāĻŽ āϭ⧇āĻ¨ā§āĻŸā§āϰāĻŋāĻ•āϞ⧇āϰ āĻĻ⧇āϝāĻŧāĻžāϞ āĻĒ⧁āϰ⧁ āĻšāϝāĻŧāĨ¤

āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ⧇āϰ Hypertension āĻāϰ āĻāĻ•āϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖ āĻ•āĻžāϰāĻŖāĨ¤

Working interpretation: Hypertensive Heart Disease with LVH.

Confidence: 0.85 — HTN āχāϤāĻŋāĻšāĻžāϏ āĻ“ Echo findings āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻāχ āĻŦā§āϝāĻžāĻ–ā§āϝāĻžāϕ⧇ āϏāĻŽāĻ°ā§āĻĨāύ āĻ•āϰ⧇; āĻ…āĻ¨ā§āϝ āĻ•āĻžāϰāĻŖ āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻžāĻĻ āϝāĻžāϝāĻŧāύāĻŋāĨ¤

3. No RWMA at Rest

āĻŦāĻŋāĻļā§āϰāĻžāĻŽ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāϝāĻŧ āϕ⧋āύ⧋ Regional Wall Motion Abnormality āĻĒāĻžāĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧāύāĻŋāĨ¤

āϤāĻŦ⧇ āĻāϰ āĻ…āĻ°ā§āĻĨ āĻāχ āύāϝāĻŧ āϝ⧇ Coronary Artery Disease āύ⧇āχāĨ¤

Resting Echo āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻĨāĻžāĻ•āϞ⧇āĻ“ Significant CAD āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

4. Cardiomegaly

CXR-āϤ⧇ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ āĻŦāĻĄāĻŧ āĻĻ⧇āĻ–āĻž āϗ⧇āϛ⧇āĨ¤

āĻāϟāĻŋ Echo-āϤ⧇ āĻĒāĻžāĻ“āϝāĻŧāĻž LVH-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāĻŽā§āĻĒāĻ°ā§āĻ•āĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϤāĻŦ⧇ X-ray-āϤ⧇ Cardiomegaly āĻŽāĻžāύ⧇āχ Heart Failure āύāϝāĻŧāĨ¤

5. Troponin I <0.006

āĻāĻ•āϟāĻŋ Troponin result āĻĻāĻŋāϝāĻŧ⧇ Acute Coronary Syndrome āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻžāĻĻ āĻĻ⧇āĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤

āĻāϰ āϜāĻ¨ā§āϝ āωāĻĒāϏāĻ°ā§āĻ—, ECG, āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ reference limit āĻāĻŦāĻ‚ āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧇ serial high-sensitivity troponin āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

Cardiomegaly āϕ⧀ āĻāĻŦāĻ‚ āϕ⧇āύ āĻšāϝāĻŧ?

Cardiomegaly (āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āφāĻ•āĻžāϰ āĻŦ⧃āĻĻā§āϧāĻŋ) āĻšāϞ⧋ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāϕ⧇āϰ āϤ⧁āϞāύāĻžāϝāĻŧ āĻŦāĻĄāĻŧ āĻšāϝāĻŧ⧇ āϝāĻžāĻ“āϝāĻŧāĻžāĨ¤ āĻāϟāĻŋ āύāĻŋāĻœā§‡ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ— āύāϝāĻŧ; āĻŦāϰāĻ‚ āĻāĻ•āϟāĻŋ Clinical/Radiological FindingāĨ¤

ā§§. āϕ⧇āύ āĻšāϝāĻŧ? (Etiology)

  • Hypertension (HTN): āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ āĻĨāĻžāĻ•āϞ⧇ āĻšāĻžāĻ°ā§āϟāϕ⧇ āĻŦ⧇āĻļāĻŋ āϚāĻžāĻĒ⧇āϰ āĻŦāĻŋāϰ⧁āĻĻā§āϧ⧇ āϰāĻ•ā§āϤ āĻĒāĻžāĻŽā§āĻĒ āĻ•āϰāϤ⧇ āĻšāϝāĻŧāĨ¤
  • Ischemic Heart Disease (IHD): āĻšā§ƒāĻĻā§â€ŒāĻĒ⧇āĻļāĻŋāϤ⧇ āϰāĻ•ā§āϤ āϏāϰāĻŦāϰāĻžāĻš āĻ•āĻŽā§‡ āĻ—āĻŋāϝāĻŧ⧇ āĻ•ā§āώāϤāĻŋ āĻšāϞ⧇ āĻšāĻžāĻ°ā§āϟ āĻŦāĻĄāĻŧ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  • Cardiomyopathy: āĻšā§ƒāĻĻā§â€ŒāĻĒ⧇āĻļāĻŋāϰ āĻ—āĻ āύ āĻŦāĻž āĻ•āĻžāĻ°ā§āϝāĻ•ā§āώāĻŽāϤāĻžāϰ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāĨ¤
  • Valvular Heart Disease: āĻšāĻžāĻ°ā§āĻŸā§‡āϰ āĻ­āĻžāϞāϭ⧇āϰ āϏāĻŽāĻ¸ā§āϝāĻžāϝāĻŧ āϚāĻžāĻĒ āĻŦāĻž āϰāĻ•ā§āϤ⧇āϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖ āĻŦ⧇āĻĄāĻŧ⧇ āϝāĻžāϝāĻŧāĨ¤

⧍. āϕ⧀āĻ­āĻžāĻŦ⧇ āĻšāϝāĻŧ? (Pathophysiology)

Chronic HTN → Increased Afterload → LV Wall Thickening (LVH) → Cardiac Remodeling → Cardiomegaly

āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻ…āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāĻŋāϤ āĻĨāĻžāĻ•āϞ⧇ āĻ•āĻŋāϛ⧁ āϰ⧋āĻ—ā§€āϰ Diastolic Dysfunction āĻāĻŦāĻ‚ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āϏāĻŽāϝāĻŧ⧇ Heart Failure āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

ā§Š. āĻāχ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āϕ⧇āύ āĻšāϝāĻŧ⧇āϛ⧇?

āϰ⧋āĻ—ā§€āϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€:

  • HTN: āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āϰāϝāĻŧ⧇āϛ⧇āĨ¤
  • Echo: Moderate Concentric LVH āĻĒāĻžāĻ“āϝāĻŧāĻž āϗ⧇āϛ⧇āĨ¤
  • CXR: Cardiomegaly āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇āĨ¤
  • LVEF: 69% — āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• Systolic FunctionāĨ¤

✅ Most Likely Cause: āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ⧇āϰ Hypertension-āĻāϰ āĻ•āĻžāϰāϪ⧇ Hypertensive Cardiac Remodeling/LVHāĨ¤

Clinical Confidence: 85% — āĻāϟāĻŋ āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž, āϤāĻŦ⧇ CXR-āϤ⧇ Cardiomegaly āĻĻ⧇āĻ–āĻž āϗ⧇āϞ⧇āχ āĻĒā§āϰāĻ•ā§ƒāϤ Heart Enlargement āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϝāĻŧ āύāĻžāĨ¤

ā§Ē. āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āϕ⧀?

āĻŽā§‚āϞāϤ āĻ•āĻžāϰāĻŖ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž:

  • BP āύāĻŋāϰāĻžāĻĒāĻĻ āϏ⧀āĻŽāĻžāϝāĻŧ āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāĻŖāĨ¤
  • āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ Antihypertensive MedicationāĨ¤
  • Salt Intake āĻ•āĻŽāĻžāύ⧋ āĻāĻŦāĻ‚ Cardiovascular Risk Factors āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāĻŖāĨ¤
  • Echo āĻ“ Clinical Follow-upāĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ BP 95/63 mmHg āĻšāĻ“āϝāĻŧāĻžāϝāĻŧ BP-āĻ•āĻŽāĻžāύ⧋āϰ āĻ“āώ⧁āϧ⧇āϰ āĻĄā§‹āϜ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

📚 References

  1. Harrison’s Principles of Internal Medicine, 22nd Edition — Hypertension and Heart Disease.
  2. Braunwald’s Heart Disease, 12th Edition — Cardiac Remodeling and Hypertrophy.
  3. 2024 ESC Hypertension Guidelines.

Final Clinical Interpretation:
Cardiomegaly on CXR, likely related to Hypertensive Heart Disease with Moderate Concentric LVH and Preserved LVEF (69%).

āĻŦāĻžāĻ‚āϞāĻž: āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ⧇āϰ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āĻĒā§āϰāĻ­āĻžāĻŦ⧇ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻŦāĻžāĻŽ āϭ⧇āĻ¨ā§āĻŸā§āϰāĻŋāĻ•āϞ⧇āϰ āĻĻ⧇āϝāĻŧāĻžāϞ āĻĒ⧁āϰ⧁ āĻšāϝāĻŧ⧇āϛ⧇, āϝāĻžāϰ āϏāĻ™ā§āϗ⧇ X-ray-āϤ⧇ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ āĻŦāĻĄāĻŧ āĻĻ⧇āĻ–āĻžāύ⧋āϰ āϏāĻŽā§āĻĒāĻ°ā§āĻ• āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤


ā§Ģ. Doctor’s Advice / Treatment Plan

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇:

CAG — Coronary Angiography

āĻŦāĻžāĻ‚āϞāĻž: āĻ•āϰ⧋āύāĻžāϰāĻŋ āĻāύāϜāĻŋāĻ“āĻ—ā§āϰāĻžāĻĢāĻŋāĨ¤

āϕ⧇āύ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• CAG āĻ•āϰāĻžāϰ āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž āĻ•āϰ⧇āϛ⧇āύ?

āϏāĻŽā§āĻ­āĻŦāϤ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻ•āϰ⧋āύāĻžāϰāĻŋ āϰāĻ•ā§āϤāύāĻžāϞāĻŋāϤ⧇ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ āϏāĻ‚āϕ⧋āϚāύ āĻŦāĻž āĻŦā§āϞāϕ⧇āϜ āφāϛ⧇ āĻ•āĻŋ āύāĻž āϤāĻž āύāĻŋāĻ°ā§āĻŖāϝāĻŧ āĻ•āϰāϤ⧇ āϚāĻžāύāĨ¤

CAG-āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡:

  • Coronary Artery Stenosis
  • Significant Coronary Obstruction
  • Multivessel Coronary Disease

āχāĻ¤ā§āϝāĻžāĻĻāĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āϝāĻžāϝāĻŧāĨ¤

Guidelines āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ

2024 ESC Chronic Coronary Syndrome Guideline āĻ…āύ⧁āϝāĻžāϝāĻŧā§€, āϖ⧁āĻŦ āĻŦ⧇āĻļāĻŋ CAD likelihood, āϗ⧁āϰ⧁āϤāϰ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϝāĻŧ āύāĻž-āĻ•āĻŽāĻž Angina, āĻ…āĻ˛ā§āĻĒ āĻĒāϰāĻŋāĻļā§āϰāĻŽā§‡ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŋāĻ‚āĻŦāĻž āωāĻšā§āϚ āĻā§āρāĻ•āĻŋāϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞ āĻĨāĻžāĻ•āϞ⧇ Invasive Coronary Angiography āωāĻĒāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

āĻ•āĻŽ āĻŦāĻž āĻŽāĻ§ā§āϝāĻŽ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāϰ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āωāĻĒāϏāĻ°ā§āĻ— āĻ“ āĻā§āρāĻ•āĻŋ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āφāϗ⧇ CCTA āĻŦāĻž Functional Imaging āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ CAG-āĻāϰ āϝāĻĨāĻžāĻ°ā§āĻĨāϤāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ Chief Complaints, ECG āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Ischemia Testing āϜāĻžāύāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤


ā§Ŧ. Prescription Drug Analysis — MedEx āĻ…āύ⧁āϝāĻžāϝāĻŧā§€Â  ***(Medicine Analysis according to Prescription)***

***1. TAB. ECOSPRIN 75 MG***

Generic Name: Aspirin 75 mg

Bangladesh Brand Name: Ecosprin 75 mg

Manufacturer: ACME Laboratories Ltd.

MedEx Therapeutic Class: Anti-platelet drugs

Pharmacological Class: Irreversible COX-1 inhibitor; Antiplatelet agent.

Prescription Dose: 0+1+0 — āĻĻ⧁āĻĒ⧁āϰ⧇ āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āĻĒāϰ⧇ ā§§āϟāĻŋāĨ¤

Duration: āϚāϞāĻŦ⧇āĨ¤

Unit Price: ā§ŗ0.80

Strip Price: ā§ŗ11.20 (14 Tablets)

Use of Purpose the Drug

Aspirin 75 mg āĻŽā§‚āϞāϤ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ:

  1. Confirmed Coronary Artery Disease
  2. Previous Myocardial Infarction
  3. Secondary Prevention of Ischemic Stroke/TIA
  4. Selected patients after PCI/Stent
  5. Selected patients after CABG

Why Doctor Prescribed This Drug in This Patient

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• IHD āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āϛ⧇āύāĨ¤

āϤāĻžāχ āϏāĻŽā§āĻ­āĻŦāϤ Coronary Thrombotic Event-āĻāϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ Aspirin āĻĻāĻŋāϝāĻŧ⧇āϛ⧇āύāĨ¤

Aspirin Platelet Aggregation āĻ•āĻŽāĻŋāϝāĻŧ⧇ āϰāĻ•ā§āϤ āϜāĻŽāĻžāϟ āĻŦāĻžāρāϧāĻžāϰ āĻĒā§āϰāĻŦāĻŖāϤāĻž āĻ•āĻŽāĻžāϝāĻŧāĨ¤

Important: Aspirin āĻ•āϰ⧋āύāĻžāϰāĻŋ āĻŦā§āϞāϕ⧇āϜ āĻĻā§‚āϰ āĻ•āϰ⧇ āύāĻžāĨ¤ āύāĻŋāĻļā§āϚāĻŋāϤ Atherosclerotic CAD āύāĻž āĻĨāĻžāĻ•āϞ⧇ āĻāĻŦāĻ‚ āφāϗ⧇ MI, PCI āĻŦāĻž Stroke-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āύāĻž āĻĨāĻžāĻ•āϞ⧇ āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻāĻŋ Aspirin-āĻāϰ benefit–bleeding risk āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Other Available Strength: Ecosprin 81 mgāĨ¤

Alternative Bangladesh Brands: Cardoprin 75 mg, Carva 75 mg, Erasprin 75 mgāĨ¤

MedEx Link: Ecosprin 75 mg


***2. TAB. OLMESAN 20 MG***

Generic Name: Olmesartan Medoxomil 20 mg

Brand Name: Olmesan 20 mg

Manufacturer: Beximco Pharmaceuticals Ltd.

MedEx Therapeutic Class: Angiotensin-II receptor blocker

Pharmacological Class: Angiotensin II AT₁ Receptor Antagonist (ARB)

Prescription Dose: 0+0+1 — āϰāĻžāϤ⧇ āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āĻĒāϰ⧇ ā§§āϟāĻŋāĨ¤

Duration: āϚāϞāĻŦ⧇āĨ¤

Unit Price: ā§ŗ10.00

Strip Price: ā§ŗ150.00 (15 Tablets)

Use of Purpose the Drug

Olmesartan āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ:

  1. Essential Hypertension
  2. Blood Pressure Control in patients with cardiovascular risk
  3. Selected patients requiring RAAS blockade

Why Doctor Prescribed This Drug in This Patient

āϰ⧋āĻ—ā§€āϰ HTN āϰāϝāĻŧ⧇āϛ⧇āĨ¤

Olmesartan Angiotensin II-āĻāϰ AT₁ receptor block āĻ•āϰ⧇ Vasoconstriction āĻ•āĻŽāĻžāϝāĻŧ āĻāĻŦāĻ‚ āϰāĻ•ā§āϤāϚāĻžāĻĒ āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāϪ⧇ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

Clinical Concern: āϰ⧋āĻ—ā§€āϰ BP 95/63 mmHgāĨ¤ āϤāĻžāχ Olmesartan-āĻāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧀āϝāĻŧāϤāĻž āĻ“ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻĄā§‹āϜ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•āϕ⧇ āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇, āĻŦāĻŋāĻļ⧇āώāϤ āϰ⧋āĻ—ā§€āϰ āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž āĻŦāĻž āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻĨāĻžāĻ•āϞ⧇āĨ¤

Monitoring: BP, Serum Creatinine, eGFR āĻ“ Serum PotassiumāĨ¤

Other Available Strengths: 10 mg, 40 mgāĨ¤

Alternative Bangladesh Brands: Olmesta 20 mg, Olmetab 20 mg, Olmetic 20 mgāĨ¤

MedEx Link: Olmesan 20 mg


***3. TAB. NIDOCARD RETARD 2.6 MG***

Generic Name: Nitroglycerin 2.6 mg

Brand Name: Nidocard Retard 2.6 mg

Manufacturer: Drug International Ltd.

MedEx Therapeutic Class: Nitrates: Coronary vasodilators

Pharmacological Class: Organic Nitrate; Nitric Oxide DonorāĨ¤

Prescription Dose: 1+0+1 — āϏāĻ•āĻžāϞ⧇ āĻ“ āϰāĻžāϤ⧇ ā§§āϟāĻŋāĨ¤

Duration: āϚāϞāĻŦ⧇āĨ¤

Unit Price: ā§ŗ5.00

Strip Price: ā§ŗ70.00 (14 Tablets)

Use of Purpose the Drug

Nitroglycerin āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ:

  1. Angina Pectoris
  2. Stable Angina Prophylaxis
  3. Symptomatic Myocardial Ischemia
  4. Acute Angina Relief — āĻĻā§āϰ⧁āϤ āĻ•āĻžāĻ°ā§āϝāĻ•āϰ Sublingual formulation

Why Doctor Prescribed This Drug in This Patient

āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• IHD āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āϛ⧇āύāĨ¤

āϏāĻŽā§āĻ­āĻŦāϤ Anginal Chest Pain āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻ“āώ⧁āϧāϟāĻŋ āĻĻāĻŋāϝāĻŧ⧇āϛ⧇āύāĨ¤

Nitroglycerin āĻĒā§āϰāϧāĻžāύāϤ Venodilation āϘāϟāĻŋāϝāĻŧ⧇ Cardiac Preload āĻ•āĻŽāĻžāϝāĻŧ, āĻĢāϞ⧇ Myocardial Oxygen Demand āĻ•āĻŽāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Important Clinical Point: Nidocard Retard 2.6 mg āĻšāϞ⧋ Sustained-release formulationāĨ¤ āĻāϟāĻŋ āĻšāĻ āĻžā§Ž āϤ⧀āĻŦā§āϰ āĻŦ⧁āϕ⧇ āĻŦā§āϝāĻĨāĻž āĻšāϞ⧇ Sublingual Nitroglycerin-āĻāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āύāϝāĻŧāĨ¤

āϰ⧋āĻ—ā§€āϰ BP āĻ•āĻŽ āĻĨāĻžāĻ•āĻžāϝāĻŧ Nitrate-induced Hypotension-āĻāϰ āĻā§āρāĻ•āĻŋ āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻāĻŋ Nitrate āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ Tolerance āĻāĻĄāĻŧāĻžāϤ⧇ dosing interval-āĻ“ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Other Available Strength: Nidocard Retard 6.4 mgāĨ¤

Other Formulations: Nitroglycerin 0.5 mg sublingual tablet āĻ“ 400 mcg/sprayāĨ¤

Alternative Bangladesh Brands: Anril SR 2.6 mg, Nitrin SR 2.6 mg, GTN SR 2.6 mgāĨ¤

MedEx Link: Nidocard Retard 2.6 mg


***4. TAB. BETALOC 25 MG***

Generic Name: Metoprolol Tartrate 25 mg

Brand Name: Betaloc 25 mg

Manufacturer: Drug International Ltd.

MedEx Therapeutic Class: āĻāχ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ Brand Page-āĻ āĻĒ⧃āĻĨāĻ• Therapeutic Class label āύ⧇āχ; āĻāϟāĻŋ Beta-blocker group-āĻāϰ āĻ“āώ⧁āϧāĨ¤

Pharmacological Class: Selective β₁-Adrenergic Receptor BlockerāĨ¤

Prescription Dose: 1+0+1 — āϏāĻ•āĻžāϞ⧇ āĻ“ āϰāĻžāϤ⧇ ā§§āϟāĻŋāĨ¤

Duration: āϚāϞāĻŦ⧇āĨ¤

Unit Price: ā§ŗ1.55

Strip Price: ā§ŗ21.70 (14 Tablets)

Use of Purpose the Drug

Metoprolol āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ:

  1. Hypertension
  2. Chronic Stable Angina
  3. Selected Tachyarrhythmias
  4. Myocardial Infarction-āĻāϰ āĻĒāϰ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϝāĻŧ
  5. Hyperthyroidism-āĻāϰ āĻ•āĻŋāϛ⧁ āωāĻĒāϏāĻ°ā§āĻ— āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāϪ⧇

Why Doctor Prescribed This Drug in This Patient

āϏāĻŽā§āĻ­āĻŦāϤ āĻĻ⧁āϟāĻŋ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻ“āώ⧁āϧāϟāĻŋ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇:

āĻĒā§āϰāĻĨāĻŽāϤ: āϰ⧋āĻ—ā§€āϰ Hypertension āύāĻŋāϝāĻŧāĻ¨ā§āĻ¤ā§āϰāĻŖāĨ¤

āĻĻā§āĻŦāĻŋāϤ⧀āϝāĻŧāϤ: Suspected IHD-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ Heart Rate āĻ“ Myocardial Oxygen Demand āĻ•āĻŽāĻžāύ⧋āĨ¤

Metoprolol β₁ receptor block āĻ•āϰ⧇ Heart Rate āĻāĻŦāĻ‚ Myocardial Contractility āĻ•āĻŽāĻžāϝāĻŧāĨ¤

Clinical Concern: āϰ⧋āĻ—ā§€āϰ Pulse 74 bpm āĻšāϞ⧇āĻ“ BP 95/63 mmHgāĨ¤ āϤāĻžāχ āĻ“āώ⧁āϧāϟāĻŋāϰ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻĄā§‹āϜ āĻ“ āϏāĻšāύāĻļā§€āϞāϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻž āϜāϰ⧁āϰāĻŋāĨ¤

LVEF 69% āĻāĻŦāĻ‚ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ MI-āĻāϰ āϤāĻĨā§āϝ āύāĻž āĻĨāĻžāĻ•āĻžāϝāĻŧ, āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ IHD-āĻāϰ āϜāĻ¨ā§āϝ Metoprolol āĻĻā§€āĻ°ā§āϘāĻŽā§‡āϝāĻŧāĻžāĻĻ⧇ cardiovascular outcome āωāĻ¨ā§āύāϤ āĻ•āϰāĻŦā§‡â€”āĻāĻŽāύ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύ⧇āĻ“āϝāĻŧāĻž āϝāĻžāϝāĻŧ āύāĻžāĨ¤ āϤāĻŦ⧇ Angina āĻŦāĻž āĻ…āĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ indication āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āϝ⧁āĻ•ā§āϤāĻŋāϝ⧁āĻ•ā§āϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Other Available Strength: Betaloc 50 mgāĨ¤

Other Formulation: Betaloc-XR 50 mg āĻ“ 100 mgāĨ¤ XR formulation-āϕ⧇ āϏāĻžāϧāĻžāϰāĻŖ Betaloc-āĻāϰ āϏāĻ™ā§āϗ⧇ āϏāϰāĻžāϏāϰāĻŋ āϏāĻŽāϤ⧁āĻ˛ā§āϝ āϧāϰ⧇ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Alternative Bangladesh Brands: Betaone 25 mg, Selomet 25 mgāĨ¤

MedEx Link: Betaloc 25 mg


***5. TAB. ATV 10 MG***

Generic Name: Atorvastatin Calcium 10 mg

Brand Name: ATV 10 mg

Manufacturer: Delta Pharma PLC.

MedEx Therapeutic Class: Other Anti-anginal & Anti-ischaemic drugs, Statins

Pharmacological Class: HMG-CoA Reductase InhibitorāĨ¤

Prescription Dose: 0+0+1 — āϰāĻžāϤ⧇ ā§§āϟāĻŋāĨ¤

Duration: āϚāϞāĻŦ⧇āĨ¤

Unit Price: ā§ŗ5.00

Strip Price: ā§ŗ50.00 (10 Tablets)

Use of Purpose the Drug

Atorvastatin āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ:

  1. Hypercholesterolemia
  2. Mixed Dyslipidemia
  3. Established Atherosclerotic Cardiovascular Disease
  4. Cardiovascular Risk Reduction
  5. Secondary Prevention following MI or certain ischemic events

Why Doctor Prescribed This Drug in This Patient

IHD āϏāĻ¨ā§āĻĻ⧇āĻš āĻŦāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āĻŖāϝāĻŧ⧇āϰ āĻ•āĻžāϰāϪ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϏāĻŽā§āĻ­āĻŦāϤ cardiovascular risk āĻ•āĻŽāĻžāϤ⧇ āĻĻāĻŋāϝāĻŧ⧇āϛ⧇āύāĨ¤

Atorvastatin LDL Cholesterol āĻ•āĻŽāĻžāϝāĻŧ āĻāĻŦāĻ‚ Atherosclerotic Plaque Stabilization-āĻ āϏāĻžāĻšāĻžāĻ¯ā§āϝ āĻ•āϰ⧇āĨ¤

Important: āϰ⧋āĻ—ā§€āϰ Lipid Profile āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤

Confirmed Chronic Coronary Disease āĻĨāĻžāĻ•āϞ⧇ Guideline āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻ…āϧāĻŋāĻ•āĻžāĻ‚āĻļ āωāĻĒāϝ⧁āĻ•ā§āϤ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ High-intensity Statin āĻŦāĻŋāĻŦ⧇āϚāĻŋāϤ āĻšāϝāĻŧāĨ¤ Atorvastatin 10 mg āĻāĻ•āϟāĻŋ Moderate-intensity dose; āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧀āϝāĻŧ intensity āύāĻŋāĻ°ā§āϧāĻžāϰāϪ⧇āϰ āϜāĻ¨ā§āϝ LDL-C, tolerance āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Other Available Strengths: ATV 20 mg, 40 mgāĨ¤

Alternative Bangladesh Brands: Atova 10 mg, Anzitor 10 mg, Avas 10 mgāĨ¤

MedEx Link: ATV 10 mg


***6. TAB. MAXPRO MUPS 20 MG***

Generic Name: Esomeprazole 20 mg

Brand Name: Maxpro MUPS 20 mg

Manufacturer: Renata PLCāĨ¤

MedEx Therapeutic Class: Proton Pump Inhibitor

Pharmacological Class: Gastric Hâē/Kâē-ATPase InhibitorāĨ¤

Prescription Dose: 1+0+1 — āϏāĻ•āĻžāϞ⧇ āĻ“ āϰāĻžāϤ⧇ āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āφāϗ⧇ ā§§āϟāĻŋāĨ¤

Duration: ā§§ āĻŽāĻžāϏāĨ¤

Unit Price: ā§ŗ10.00

Strip Price: ā§ŗ140.00 (14 Tablets)

Use of Purpose the Drug

Esomeprazole āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻšāϝāĻŧ:

  1. GERD
  2. Gastritis-āĻāϰ āĻ•āĻŋāϛ⧁ Acid-related Symptoms
  3. Peptic Ulcer Disease
  4. Erosive Esophagitis
  5. Selected patients requiring GI protection while using NSAIDs or Antiplatelet therapy

Why Doctor Prescribed This Drug in This Patient

āϏāĻŽā§āĻ­āĻŦāϤ Aspirin āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϏāĻŽāϝāĻŧ Gastrointestinal Complication-āĻāϰ āĻā§āρāĻ•āĻŋ āĻ•āĻŽāĻžāύ⧋āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤

āϤāĻŦ⧇ āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ Ulcer āĻŦāĻž GI Bleeding-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āωāĻ˛ā§āϞ⧇āĻ– āύ⧇āχāĨ¤ āϤāĻžāχ PPI āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻ“ āĻĻāĻŋāύ⧇ āĻĻ⧁āχāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϝ⧌āĻ•ā§āϤāĻŋāĻ•āϤāĻž āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻā§āρāĻ•āĻŋāϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

Other Available Strength: Maxpro MUPS 40 mgāĨ¤

Alternative Bangladesh Brands: Nexum MUPS 20 mg, Nexpro MUPS 20 mg, Maxima MUPS 20 mgāĨ¤

MedEx Link: Maxpro MUPS 20 mg


ā§­. Bangladesh Doctors āϏāĻžāϧāĻžāϰāĻŖāϤ IHD with HTN-āĻ āϕ⧋āύ āϕ⧋āύ Drug āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰ⧇āύ?

āϰ⧋āϗ⧇āϰ āϧāϰāύ, Angina-āĻāϰ āωāĻĒāĻ¸ā§āĻĨāĻŋāϤāĻŋ, BP, Heart Rate, Coronary Anatomy āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻā§āρāĻ•āĻŋ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻ“āώ⧁āϧ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāĻž āĻšāϝāĻŧāĨ¤

āύāĻŋāĻšā§‡āϰ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ, āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāϤ⧁āύ Prescription āύāϝāĻŧāĨ¤

Drug ClassGeneric / Bangladesh Brand Exampleāϕ⧇āύ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšāϝāĻŧ
AntiplateletAspirin — Ecosprin, CardoprinConfirmed Atherosclerotic CAD-āϤ⧇ Thrombotic Event Prevention
P2Y12 InhibitorClopidogrel — Clopid, ClopiletāύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ CAD, ACS āĻŦāĻž PCI āĻĒāϰāĻŋāĻ¸ā§āĻĨāĻŋāϤāĻŋāϤ⧇
StatinAtorvastatin — ATV, AtovaLDL āĻ•āĻŽāĻžāύ⧋ āĻ“ Cardiovascular Risk Reduction
High-intensity Statin OptionRosuvastatin — RosuvaāωāĻĒāϝ⧁āĻ•ā§āϤ āϰ⧋āĻ—ā§€āϰ LDL Reduction āĻ“ Secondary Prevention
ARBOlmesartan — Olmesan, OlmestaHypertension Control
Beta-blockerMetoprolol — Betaloc, BetaoneAngina, Heart Rate āĻ“ BP Control
Calcium Channel BlockerAmlodipine — AmdocalHTN āĻ“ Angina Management
NitrateNitroglycerin — Nidocard, AnrilAngina Relief/Prevention
PPIEsomeprazole — Maxpro MUPS, Nexum MUPSGI Protection-āĻāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ āĻĨāĻžāĻ•āϞ⧇

āωāĻĻāĻžāĻšāϰāĻŖ āĻšāĻŋāϏ⧇āĻŦ⧇ Clopidogrel, Amlodipine āĻ“ Rosuvastatin-āĻāϰ āωāĻ˛ā§āϞāĻŋāĻ–āĻŋāϤ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļāĻŋ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄāϗ⧁āϞ⧋ MedEx-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϰāϝāĻŧ⧇āϛ⧇āĨ¤

āĻāχ āϰ⧋āĻ—ā§€āϰ āĻŦāĻ°ā§āϤāĻŽāĻžāύ BP āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϝāĻŧ āύāϤ⧁āύ Antihypertensive āĻŦāĻž Antianginal Drug āϝ⧋āĻ— āĻ•āϰāĻžāϰ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻĻ⧇āĻ“āϝāĻŧāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤


ā§Ž. Differential Diagnosis

āĻāχ āϰ⧋āĻ—ā§€āϰ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ āĻŦāĻŋāĻŦ⧇āĻšā§āϝ āϰ⧋āĻ—āϗ⧁āϞ⧋:

Possible DiagnosisSupporting EvidenceLimitation
Hypertensive Heart DiseaseHTN + Moderate Concentric LVHLVH-āĻāϰ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻžāϰāĻŖ āĻŦāĻžāĻĻ āĻĻ⧇āĻ“āϝāĻŧāĻž āĻšāϝāĻŧāύāĻŋ
Chronic Coronary SyndromeāϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ IHD Diagnosis āĻāĻŦāĻ‚ Antianginal PrescriptionAngina History, ECG, Ischemia Test āĻ…āύ⧁āĻĒāĻ¸ā§āĻĨāĻŋāϤ
Obstructive Coronary Artery DiseaseāϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• CAG āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž āĻ•āϰ⧇āϛ⧇āύAngiographic confirmation āύ⧇āχ
Coronary Microvascular DysfunctionIHD-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•āĻžāϰāĻŖāϕ⧋āύ⧋ diagnostic evidence āύ⧇āχ
Hypertrophic CardiomyopathyLVH-āĻāϰ āĻāĻ•āϟāĻŋ differentialāĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰāĻŋāĻĒā§‹āĻ°ā§āĻŸā§‡ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāϰ āϤāĻĨā§āϝ āύ⧇āχ
Heart Failure with Preserved EFLVH āĻāĻ•āϟāĻŋ associated finding āĻšāϤ⧇ āĻĒāĻžāϰ⧇HF symptoms āĻ“ objective filling-pressure evidence āύ⧇āχ

āφāĻŽāĻžāϰ Clinical Interpretation

āĻāĻ–āĻžāύ⧇ āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āĻ­āĻžāϞ⧋āĻ­āĻžāĻŦ⧇ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ Structural Abnormality āĻšāϞ⧋:

Moderate Concentric Left Ventricular Hypertrophy.

HTN-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āĻĨāĻžāĻ•āĻžāϝāĻŧ Hypertensive Heart Disease āĻāĻ•āϟāĻŋ āϝ⧁āĻ•ā§āϤāĻŋāϝ⧁āĻ•ā§āϤ Working DiagnosisāĨ¤

āϤāĻŦ⧇ IHD āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāϤ⧇ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϤāĻĨā§āϝ āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤


⧝. Doctor’s Diagnosis vs My Clinical Assessment

Prescribing Doctor’s Diagnosis

IHD with HTN

āĻŦāĻžāĻ‚āϞāĻž: āχāĻ¸ā§āϕ⧇āĻŽāĻŋāĻ• āĻšā§ƒāĻĻā§â€Œāϰ⧋āϗ⧇āϰ āϏāĻ™ā§āϗ⧇ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒāĨ¤

My Working Clinical Assessment

Suspected Chronic Coronary Syndrome (IHD), with a documented history of Hypertension and Moderate Concentric Left Ventricular Hypertrophy, preserved LVEF (69%).

āĻŦāĻžāĻ‚āϞāĻž:

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻ•ā§āϰāύāĻŋāĻ• āĻ•āϰ⧋āύāĻžāϰāĻŋ āĻšā§ƒāĻĻā§â€Œāϰ⧋āĻ—; āϏāĻ™ā§āϗ⧇ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ, āĻŦāĻžāĻŽ āϭ⧇āĻ¨ā§āĻŸā§āϰāĻŋāĻ•āϞ⧇āϰ āĻĻ⧇āϝāĻŧāĻžāϞ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāĻ¤ā§āϰāĻžāϝāĻŧ āĻĒ⧁āϰ⧁ āĻšāĻ“āϝāĻŧāĻž āĻāĻŦāĻ‚ āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āϏāĻŋāĻ¸ā§āĻŸā§‹āϞāĻŋāĻ• āĻĒāĻžāĻŽā§āĻĒāĻŋāĻ‚ āĻ•ā§āώāĻŽāϤāĻžāĨ¤

Diagnosis Confidence Assessment

Clinical FindingConfidenceJustification
Documented HTN0.99āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰ⧇āϛ⧇āύ
Moderate Concentric LVH0.99Echo-āϤ⧇ āϏāϰāĻžāϏāϰāĻŋ āωāĻ˛ā§āϞ⧇āĻ– āϰāϝāĻŧ⧇āϛ⧇
Preserved LV Systolic Function0.99LVEF 69%
Hypertensive Heart Disease0.85HTN history + LVH
Suspected IHD0.65āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ Diagnosis āϰāϝāĻŧ⧇āϛ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻžāϰ āϤāĻĨā§āϝ āύ⧇āχ
Confirmed Obstructive CADāύāĻŋāĻ°ā§āϧāĻžāϰāĻŖāϝ⧋āĻ—ā§āϝ āύāϝāĻŧCAG/CCTA āĻŦāĻž āĻ…āĻ¨ā§āϝ āϝāĻĨ⧇āĻˇā§āϟ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχ

āĻāϗ⧁āϞ⧋ āϤāĻĨā§āϝ⧇āϰ āĻ“āĻĒāϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋ āĻ•āϰ⧇ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇āϰ Confidence Score, āϰ⧋āĻ—āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§ƒāϤ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻžāϰ āĻĒāϰāĻŋāϏāĻ‚āĻ–ā§āϝāĻžāύ āύāϝāĻŧāĨ¤

Doctor’s Dx āĻāĻŦāĻ‚ āφāĻŽāĻžāϰ Assessment āĻ•āĻŋ Similar?

āφāĻ‚āĻļāĻŋāĻ•āĻ­āĻžāĻŦ⧇ SimilarāĨ¤

āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ HTN Diagnosis āĻāĻŦāĻ‚ LVH-āĻāϰ āϏāĻ™ā§āϗ⧇ āφāĻŽāĻžāϰ Assessment āϏāĻžāĻŽāĻžā§āϜāĻ¸ā§āϝāĻĒā§‚āĻ°ā§āĻŖāĨ¤

āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻšāϞ⧋, āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• IHD āϞāĻŋāϖ⧇āϛ⧇āύ, āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āĻĨ⧇āϕ⧇ Confirmed IHD āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻž āĻ•āϰāĻž āϝāĻžāĻšā§āϛ⧇ āύāĻžāĨ¤ āϤāĻžāχ āφāĻŽāĻžāϰ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ⧇ Suspected IHD āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦ⧇āĻļāĻŋ āϏāϤāĻ°ā§āĻ• āĻ“ āϝāĻĨāĻžāϝāĻĨāĨ¤


ā§§ā§Ļ. Prescription-āĻ Final Dx āϕ⧀ āϞāĻŋāĻ–āĻŦ⧇āύ?

āϝāĻĻāĻŋ āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āϕ⧋āύ⧋ Clinical History āĻŦāĻž Confirmatory Investigation āύāĻž āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ āύāĻŋāĻšā§‡āϰ Working Diagnosis āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

Recommended Working Diagnosis

Dx: Suspected Chronic Coronary Syndrome (IHD) with Hypertension and Moderate Concentric LVH; Preserved LVEF (69%).

āĻŦāĻžāĻ‚āϞāĻž:

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻĻā§€āĻ°ā§āϘāĻ¸ā§āĻĨāĻžāϝāĻŧā§€ āχāĻ¸ā§āϕ⧇āĻŽāĻŋāĻ• āĻšā§ƒāĻĻā§â€Œāϰ⧋āĻ—, āϏāĻ™ā§āϗ⧇ āωāĻšā§āϚ āϰāĻ•ā§āϤāϚāĻžāĻĒ āĻ“ āĻŦāĻžāĻŽ āϭ⧇āĻ¨ā§āĻŸā§āϰāĻŋāĻ•āϞ⧇āϰ āĻŽāĻžāĻāĻžāϰāĻŋ āĻŽāĻžāĻ¤ā§āϰāĻžāϰ āĻĻ⧇āϝāĻŧāĻžāϞ āĻĒ⧁āϰ⧁ āĻšāĻ“āϝāĻŧāĻž; āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āϏāĻŋāĻ¸ā§āĻŸā§‹āϞāĻŋāĻ• āĻĒāĻžāĻŽā§āĻĒāĻŋāĻ‚ āĻ•ā§āώāĻŽāϤāĻž āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ•āĨ¤

Short Clinical Version

Dx: Suspected IHD with HTN and Concentric LVH.

āϝāĻĻāĻŋ āϰ⧋āĻ—ā§€āϰ āĻĒā§‚āĻ°ā§āĻŦāĻŦāĻ°ā§āϤ⧀ CAG, CCTA, MI āĻŦāĻž āĻ…āĻ¨ā§āϝ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ āĻĒāϰ⧀āĻ•ā§āώāĻžāϝāĻŧ CAD āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϝāĻŧ⧇ āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ āϏ⧇āχ āĻĒā§āϰāĻŽāĻžāĻŖ āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ Established CAD/IHD āϞ⧇āĻ–āĻž āϝ⧇āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤


ā§§ā§§. Doctor’s Action Plan

Step 1 — Immediate Clinical Reassessment

āĻŦāĻ°ā§āϤāĻŽāĻžāύ BP āĻ“ Pulse āĻĒ⧁āύāϰāĻžāϝāĻŧ āĻĒāϰāĻŋāĻŽāĻžāĻĒ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

  • Sitting āĻ“ Standing BP
  • Pulse Rate
  • Orthostatic Symptoms
  • Chest Pain History
  • Exertional Dyspnea
  • Syncope āĻŦāĻž Presyncope
  • āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϏāĻŦ āĻ“āώ⧁āϧ āĻāĻŦāĻ‚ āĻĄā§‹āϜ

āĻŦāĻŋāĻļ⧇āώ āϗ⧁āϰ⧁āĻ¤ā§āĻŦ: āϰ⧋āĻ—ā§€ āϝāĻĻāĻŋ āĻāĻ–āύ⧋ Olmesan, Betaloc āĻ“ Nidocard āĻ—ā§āϰāĻšāĻŖ āĻ•āϰ⧇āύ āĻāĻŦāĻ‚ BP āĻ•āĻŽ āĻĨāĻžāϕ⧇, āϤāĻžāĻšāϞ⧇ Prescribing Cardiologist-āĻāϰ āĻĻā§āϰ⧁āϤ Medication Review āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āϤ⧀āĻŦā§āϰ āĻŦ⧁āϕ⧇ āĻŦā§āϝāĻĨāĻž, āĻļā§āĻŦāĻžāϏāĻ•āĻˇā§āϟ, āĻ…āĻœā§āĻžāĻžāύ āĻšāĻ“āϝāĻŧāĻž āĻŦāĻž āϗ⧁āϰ⧁āϤāϰ āĻĻ⧁āĻ°ā§āĻŦāϞāϤāĻž āĻĨāĻžāĻ•āϞ⧇ āϜāϰ⧁āϰāĻŋ āĻŦāĻŋāĻ­āĻžāϗ⧇ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

Step 2 — Further Investigations

InvestigationPurpose
12-lead ECGIschemic Change, Arrhythmia, LVH
Repeat Echocardiography, if clinically indicatedāĻŦāĻ°ā§āϤāĻŽāĻžāύ LV Structure āĻ“ Function
Fasting Lipid ProfileLDL-C āĻāĻŦāĻ‚ Statin Intensity
HbA1cDiabetes Screening
CBCAnemia āĻ“ Baseline Hemoglobin
Serum ElectrolytesSodium, Potassium
Serum Creatinine + eGFRRenal Function, āĻŦāĻŋāĻļ⧇āώāϤ Contrast āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āφāϗ⧇
Urine ACRHypertensive Kidney Damage āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ
CCTA / Functional ImagingClinical Likelihood āĻ…āύ⧁āϝāĻžāϝāĻŧā§€ CAD Evaluation
CAGCardiologist-āĻāϰ Risk Assessment āĻ“ Indication āĻ…āύ⧁āϝāĻžāϝāĻŧā§€

CAG-āĻāϰ āφāϗ⧇ renal function āĻ“ contrast-related risks āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Step 3 — Medication Optimization

āĻŦāĻ°ā§āϤāĻŽāĻžāύ Prescription Review āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

āĻŦāĻŋāĻļ⧇āώ āĻ•āϰ⧇:

Olmesartan + Metoprolol + Nitroglycerin

āĻāχ āϏāĻŽāĻ¨ā§āĻŦāϝāĻŧ⧇ BP āĻ…āϤāĻŋāϰāĻŋāĻ•ā§āϤ āĻ•āĻŽāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āϰāϝāĻŧ⧇āϛ⧇āĨ¤

āĻ āĻ›āĻžāĻĄāĻŧāĻž āύāĻŋāĻļā§āϚāĻŋāϤ CAD āĻĨāĻžāĻ•āϞ⧇ Statin Intensity āĻāĻŦāĻ‚ Aspirin-āĻāϰ indication āĻ“ bleeding risk āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤

Step 4 — Referral

Refer to: Consultant Cardiologist / Interventional Cardiologist

āĻ•āĻžāϰāĻŖ:

  1. Suspected IHD-āĻāϰ āϝāĻĨāĻžāϝāĻĨ āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ
  2. CAG Indication āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ
  3. Low BP āĻāĻŦāĻ‚ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āĻ“āώ⧁āϧ⧇āϰ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ
  4. LVH āĻ“ Hypertension Management

Referral Note:

A 56-year-old female with a documented history of hypertension and suspected ischemic heart disease. Previous echocardiography revealed moderate concentric LVH with preserved LVEF (69%). BP was recorded as 95/63 mmHg. Kindly evaluate the indication for coronary angiography, assess current cardiovascular status, and review antianginal and antihypertensive therapy.


⧧⧍. Overview / Summary

Clinical ParameterFinal Assessment
Doctor’s DiagnosisIHD with HTN
Main Structural FindingModerate Concentric LVH
LVEF69%, preserved
Current Recorded BP95/63 mmHg
Recorded Pulse74 bpm
CXRCardiomegaly
Confirmed CADNot established from available records
Treatment PlanCAG
Major Medication ConcernPossible BP-lowering effects of multiple drugs
ReferralCardiologist
Recommended Working DxSuspected IHD with HTN and Moderate Concentric LVH

āφāϰ⧇āĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻ…āϏāĻ‚āĻ—āϤāĻŋ: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āĻĒāϰ⧇ āϤāĻžāϰāĻŋāĻ– 05/01/2026, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏāĻŋāϞ⧇āϰ āϤāĻžāϰāĻŋāĻ– 05 Jan 2025 āĻĻ⧇āĻ–āĻž āϝāĻžāĻšā§āϛ⧇āĨ¤ Echo-āϰ āϤāĻžāϰāĻŋāĻ– 05/01/2024āĨ¤ āĻŽā§‚āϞ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžāϰ āύāĻĨāĻŋ āĻĻāĻŋāϝāĻŧ⧇ āϤāĻžāϰāĻŋāĻ–āϗ⧁āϞ⧋ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āĻĒā§āϰāϝāĻŧā§‹āϜāύāĨ¤


ā§§ā§Š. Reference List

Standard Medical Textbooks

  1. Harrison’s Principles of Internal Medicine. 22nd Edition. McGraw Hill. Sections on Chronic Coronary Disease, Hypertension and Cardiovascular Diagnosis.
  2. Davidson’s Principles and Practice of Medicine. 24th Edition. Elsevier. Cardiovascular Disease chapters.
  3. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 12th Edition. Elsevier. Sections on Stable Ischemic Heart Disease and Hypertensive Heart Disease.
  4. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th Edition. McGraw Hill. Sections on Antihypertensive, Antianginal, Antiplatelet and Lipid-lowering Drugs.

International Guidelines

1. ESC Guidelines 2024

Vrints CJM, et al. 2024 ESC Guidelines for the Management of Chronic Coronary Syndromes.

European Heart Journal. 2024;45:3415–3537.

DOI: 10.1093/eurheartj/ehae177.

2. AHA/ACC Guideline 2023

Virani SS, et al. 2023 AHA/ACC Multisociety Guideline for the Management of Patients with Chronic Coronary Disease.

Circulation. 2023;148:e9–e119.

DOI: 10.1161/CIR.0000000000001168.

3. ESC Guidelines 2024 — Hypertension

2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension.

European Society of Cardiology.

Drug Reference

MedEx Bangladesh: āĻ“āώ⧁āϧ⧇āϰ Generic Name, Therapeutic Class, āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļāĻŋ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ, Strength āĻāĻŦāĻ‚ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āĻŽā§‚āĻ˛ā§āϝ MedEx-āĻāϰ āϏāĻ‚āĻļā§āϞāĻŋāĻˇā§āϟ Brand Pages āĻĨ⧇āϕ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšāϝāĻŧ⧇āϛ⧇āĨ¤ āĻŦāĻžāϜāĻžāϰāĻŽā§‚āĻ˛ā§āϝ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤


✅ Final Clinical Assessment

Suspected Chronic Coronary Syndrome (IHD) with Hypertension and Moderate Concentric LVH; Preserved LV Systolic Function (LVEF 69%).

āϏāĻŦāĻšā§‡āϝāĻŧ⧇ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ: āϰ⧋āĻ—ā§€āϰ LVH āĻāĻŦāĻ‚ HTN-āĻāϰ āχāϤāĻŋāĻšāĻžāϏ āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻŋāϤ āĻšāϞ⧇āĻ“ āĻ•āϰ⧋āύāĻžāϰāĻŋ āφāĻ°ā§āϟāĻžāϰāĻŋāϤ⧇ āĻŦā§āϞāϕ⧇āϜ āĻŦāĻž Myocardial Ischemia āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϝāĻŧāύāĻŋāĨ¤ āϤāĻžāχ CAG-āĻāϰ āĻĒā§āϰāϝāĻŧā§‹āϜāύ⧀āϝāĻŧāϤāĻž āĻāĻŦāĻ‚ āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻ•āĻŽ āϰāĻ•ā§āϤāϚāĻžāĻĒ⧇āϰ āϏāĻ™ā§āϗ⧇ Antianginal āĻ“ Antihypertensive āĻ“āώ⧁āϧāϗ⧁āϞ⧋āϰ āϏāĻŽā§āĻĒāĻ°ā§āĻ• Cardiologist-āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžāϝāĻŧāύ āĻ•āϰāĻžāχ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻĒāĻĻāĻ•ā§āώ⧇āĻĒāĨ¤

Md.Rafiqul Islam Lipu

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top